These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis. Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450 [TBL] [Abstract][Full Text] [Related]
4. Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. Patti F; Reggio E; Palermo F; Fiorilla T; Politi G; Nicoletti A; Reggio A J Neurol; 2004 Dec; 251(12):1502-6. PubMed ID: 15645351 [TBL] [Abstract][Full Text] [Related]
5. Translating new insights into treatment optimisation in multiple sclerosis. Fazekas F; Kieseier BC J Neurol Sci; 2009 Feb; 277 Suppl 1():S1-2. PubMed ID: 19200857 [No Abstract] [Full Text] [Related]
6. What is new in the treatment of multiple sclerosis? Weinstock-Guttman B; Jacobs LD Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827 [TBL] [Abstract][Full Text] [Related]
7. Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis. Jeffery DR Neurology; 2004 Dec; 63(12 Suppl 6):S41-6. PubMed ID: 15623670 [TBL] [Abstract][Full Text] [Related]
8. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up. Reggio E; Nicoletti A; Fiorilla T; Politi G; Reggio A; Patti F J Neurol; 2005 Oct; 252(10):1255-61. PubMed ID: 15940386 [TBL] [Abstract][Full Text] [Related]
9. Moving on to second-line therapies in pediatric MS: Immunosuppression with cyclophosphamide. Yeh EA; Weinstock-Guttman B Neurology; 2009 Jun; 72(24):2064-5. PubMed ID: 19439721 [No Abstract] [Full Text] [Related]
10. Concomitant therapy for multiple sclerosis. Stuart WH; Vermersch P Neurology; 2004 Dec; 63(11 Suppl 5):S28-34. PubMed ID: 15596733 [TBL] [Abstract][Full Text] [Related]
11. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis. Banwell B; Tremlett H Neurology; 2005 Mar; 64(5):778-9. PubMed ID: 15753408 [No Abstract] [Full Text] [Related]
12. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. Patti F; Amato MP; Filippi M; Gallo P; Trojano M; Comi GC J Neurol Sci; 2004 Aug; 223(1):69-71. PubMed ID: 15261564 [TBL] [Abstract][Full Text] [Related]
13. Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies. Kieseier BC; Hartung HP Exp Neurol; 2007 Jan; 203(1):1-4. PubMed ID: 17069803 [No Abstract] [Full Text] [Related]
15. Influences on cognition by immunosuppression and immunomodulation in multiple sclerosis. Tumani H; Uttner I J Neurol; 2007 May; 254 Suppl 2():II69-72. PubMed ID: 17503133 [TBL] [Abstract][Full Text] [Related]
16. Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies. Giovannoni G Neurology; 2003 Nov; 61(9 Suppl 5):S13-7. PubMed ID: 14610104 [TBL] [Abstract][Full Text] [Related]